主页 > 医药科学 >
【drug-news】赛特里斯制药公司发布六千万美元的
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. 剑桥市，马萨诸塞州－商业短讯－赛特里斯制药公司今天宣称向美国证券交易委员会提出了首次发行股票的说明。股票的份额已经提出，但是股价还没有确定。
J.P. Morgan Securities Inc. will serve as the sole book-running manager for the offering. CIBC World Markets Corp., Piper Jaffray & Co., JMP Securities LLC, and Rodman & Renshaw, LLC are acting as co-managers for the offering. J.P.摩根证券公司将是本次股份发行的唯一承销商，CIBC World Markets Corp., Piper Jaffray & Co., JMP Securities LLC, and Rodman & Renshaw, LLC公司作为联席经办人。
About Sirtris Pharmaceuticals 关于赛特里斯制药公司
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. The company's headquarters are in Cambridge, Massachusetts. 赛特里斯制药公司是一家生物制药公司，关注于自主知识产权、口服、具有潜在抗衰老作用的小分子药物，包括2型糖尿病之类的代谢疾病。候选药物设计成为卡路里限制作用的药物，但不需患者改变饮食习惯，它是通过称为SIRT1酶起作用，这种酶是一种抗衰老酶sirtuins。公司总部位于马萨诸塞州剑桥市。
http://www.biospace.com/news_story.aspx?StoryId=47567 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-23 17:12
医学,生命科学网